First-line treatment in small cell lung cancer;Erstlinientherapie des kleinzelligen lungenkarzinoms (SCLC)

Onkologe

Volumn 11, Issue 7, 2005, Pages 722-729

  Reck, M ^a   Niederle, N ^b   Thomas, M ^c   Gatzemeier, U ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemotherapy; Dose dense therapy; Maintenance therapy; Novel agents; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; MARIMASTAT; METALLOPROTEINASE INHIBITOR; NAVELBINE; OBLIMERSEN; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; R 11577; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG MEGADOSE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; NEUTROPENIA; RANDOMIZATION; REVIEW; VACCINATION;

EID: 22244487670     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-005-0887-4     Document Type: Review

References (39)

1. Ferlay J, Bray F, Pisani P, Parkin D (2001) Globocan 2000. Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press
2. Levi F, Lucchini F, Negri E et al. (1999) Cancer mortality in Europe, 1990-1994 and an overview of trends from 1955 to 1994. Eur J Cancer 35:1477-1516
3. Khuder SA, Mutgi AB (2001) Effect of smoking cessation on major histologic types of lung cancer. Chest 120:1577-1583
4. Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4:31-42
5. Wittekind CH, Wagner G (Hrsg) für die UICC (1997) TNM Klassifikation maligner Tumoren. Springer, Berlin Heidelberg New-York
6. Stahel RA, Ginsberg R, Havemann K et al. (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5:119-126
7. Deutsche Krebsgesellschaft. Therapie des kleinzelligen Lungenkarzinoms aus Kurzgefasste Interdisziplinäre Leitlinien 2004, Diagnostik und Therapie maligner Erkrankungen. Zuckschwerdt, München Bern Wien New York, S 101-113
8. Lassen UN, Hirsch FR, Osterlind K et al. (1998) Outcome of combination chemotherapy in extensive stage small cell lung cancer: any treatment related progress? Lung Cancer 20:151-160
9. Sandler AB (2003) Chemotherapy for Small Cell Lung Cancer. Seminars in Oncology 30:9-25
10. Erridge SC, Murray N (2003) Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer: Issues of Timing, Volumes, Dose and Fractionation. Semin Oncol 30:26-37
11. Fried DB, Morris DE, Poole C et al. (2004) Systematic Review Evaluating Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol 22:4785-4793
12. Fukuoka M, Furuse K, Saijo N et al. (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861
13. Sundstrøm S, Bremnes RM, Kaasa S et al. (2002) Cisplatin and Etoposide Regimen is Superior to Cyclophosphamide, Epirubicin, and Vincristine in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years' Follow-Up. J Clin Oncol 20:4665-4672
14. Wolf M, Tebbe S, Fink T (2004) First-Line Chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer 45 [Suppl 2]:223-234
15. Stupp R, Monnerat C, Turrisi AT III et al. (2004) Small cell lung cancer: state of the art and future perspectives. Lung Cancer 45:105-117
16. Schiller JH, Adak S, Cell D et al. (2001) Topotecan versus observation after cisplatin plus etoposide in extensive small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114-2122
17. Hanna H, Sandler AB, Loehrer PJ et al. (2002) Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 13:642-650
18. Niederle N, Krischke W, Schulz U et al. (1982) Untersuchungen zur kurzzeitigen Induktions- und zyklischen Erhaltungstherapie beim inoperablen kleinzelligen Lungenkarzinom. Klin Wochenschrift 60:829-838
19. Steward WP, von Pawel J, Gatzemeier U et al. (1998) Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 16:642-650
20. Thatcher N, Girling DJ, Hopwood P et al. (2000) Improving survival without reducing quality of life in small cell lung cancer patients by increasing the dose intensity of chemotherapy with granulocyte colony stimulating factor support: Results of a British Medical Research Council multicenter randomized trial. J Clin Oncol 18:395-404
21. Ardizzoni A, Tjan-Heijnen V, Postmus P et al. (2002) Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer - Lung Cancer Group phase III trial - 08923. J Clin Oncol 20:3947-3955
22. Sculier JP, Paesmans M, Lecomte J et al., European Lung Cancer Working Party (2001) A three-arm phase III randomised trial assessing, in patients extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor oral antibiotics. Br J Cancer 85:1444-1451
23. James L, Rudd R, Gower N et al. (2002) A phase III comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer. Proc Am Soc Clin Oncol 21:2193 (1170)
24. Noda K, Nishiwaki Y, Kawahara M et al., Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91
25. Gervais R, Quoix E, Breton J et al. (2001) Randomised phase II study of topotecan/cisplatin (TC) versus topotecan/etoposide (TE) in patients with untreated, extensive disease, small cell lung cancer. Proc Am Soc Clin Oncol 20:1268
26. Reck M, Jagos U, Grunwald F et al. (2003) Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide - A phase II study. Am Soc Clin Oncol Lung Cancer 39:63-69
27. Reck M, von Pawel J, Macha HN et al. (2003) Randomized Phase III Trial of Paclitaxel, Etoposide and Carboplatin versus Carboplatin, Etoposide and Vincristine in Patients with Small-Cell Lung Cancer. J Natl Cancer Inst 95:1118-1127
28. Mavroudis D, Papadakis E, Veslemes M et al. (2001) A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12:463-470
29. Niell HB, Herndon JE, Miller AA et al. (2002) Randomized phase III intergroup trial (CALGB 7932) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer (ED SCLC). Proc Am Soc Clin Oncol 21:#1169
30. Shepherd FA, Giaccone G, Seymour L et al. (2002) Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institue of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439
31. Rigas J, Denham C, Rinaldi D et al. (2003) Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. Proc Am Soc Clin Oncol 22:628 (#2525)
32. Johnson B, Fisher B, Fisher T, Dunlop D et al. (2002) Phase II study of STI571 (Gleevec™) for patients with small cell lung cancer. Proc Am Soc Clin Oncol 21:293a (#1171)
33. Heymach JV, De Porre PM, DeVore RF et al. (2002) Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC) Proc Am Soc Clin Oncol 21:319a (#1275)
34. Krug LM, Crapanzano JP, Miller VA et al. (2004) C-kit protein expression in tumor specimens as a predictor of sensitivity to imatinib mesylate in patients with small cell lung cancer (SCLC): A phase II clinical trial. Proc Am Soc Clin Oncol 23:#7218
35. Rudin CM MK, Hoffman PC, Edelman MJ et al. (2004) Phase I study of G3139, a bcl-2 Antisense Oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22:1110-1117
36. Giaccone G, Debruyne C, Felip E et al. (2004) Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC), following reponse to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). Proc Am Soc Clin Oncol 23:#7020
37. Livingston RB, Moore TN, Heilbrun L et al. (1978) Small cell carcinomas of the lung. Combined chemotherapy and radiation. A Southwest Group Study inn. Intern Med 88:194
38. Klastersky J, Sculier JP, Dumont JP (1986) Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. Cancer 56:71-75
39. Gatzemeier U, Hossfeld DK, Neuhauss R et al. (1992) Combination Chemotherapy with Carboplatin, Etoposide and Vincristin as First-Line Treatment in Small-Cell Lung Cancer. J Clin Oncol 10:818-823